Truist Financial raised the stock rating for Corcept Therapeutics, and a director sold company stock.
2 reports, 2 independent
Updated Jul 21
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Truist Financial raised the stock rating for Corcept Therapeutics, and a director sold company stock.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Corcept Therapeutics
American pharmaceutical company
-
Truist Financial
American bank holding company, formerly known as BB&T Corporation
- MarketBeat aggregates data on Inventiva's stock, and Truist Financial has started coverage of the company.
- Bank of America boosted its price target and gave a buy rating for Guardian Pharmacy Services, Inc. on September 15, 2026. Truist Financial also boosted its target price and gave a buy rating on the same day.
Related events
- Investor activity regarding Corcept Therapeutics, including RBC boosting holdings and Amundi buying, was disclosed via SEC filings.
- Fifth Third Bancorp acquired a new stake in Truist Financial stock, leading to institutional investment disclosures.
- Corcept Therapeutics disclosed insider trading activity via SEC filings.
- Truist Financial reissued a 'hold' rating and set a target price for Inspire Medical Systems.
- Treace Medical Concepts disclosed a purchase in an SEC filing, and Truist Financial increased its target price for the company.